Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
Elke Jäger,Mark Ringhoffer,Hans Peter Dienes,Michael Arand,Julia Karbach,Dirk Jäger,Christiane Ilsemann,Manfred Hagedorn,Franz Oesch,Alexander Knuth +9 more
323
TL;DR: It is concluded that systemic GM‐CSF enhances immune responses to melanoma‐associated peptides and supports CTL‐mediated tumor rejection in vivo.
read more
Abstract: Peptide epitopes derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for MHC-restricted cytotoxic T lymphocytes (CTL). The characterization of multiple CTL-defined antigenic determinants has opened possibilities of development of antigen-targeted vaccines. In the present study, we determined CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase, and gp100/Pmel17 in 3 HLA-A2+ melanoma patients. Then, we assessed the immune responses to synthetic melanoma-associated peptides injected intradermally. After 3 cycles of immunization with peptide alone, we used systemic GM-CSF as an adjuvant during the fourth cycle of immunization. Enhanced DTH reactions and CD8+ CTL responses were observed after treatment with systemic GM-CSF. Immunohistochemical characterization of DTH-constituting elements revealed infiltrates of CD4+ and CD8+ T lymphocytes and strong expression of IL-2 and gammaIFN, suggesting the activation of CD4+ ThI and CD8+ CTL by peptides presented by MHC-class-I molecules of dermal APC. Objective tumor regression was documented in all patients. We conclude that systemic GM-CSF enhances immune responses to melanoma-associated peptides and supports CTL-mediated tumor rejection in vivo.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates
TL;DR: Data show induction of CD8+ T cells specific for the melanosomal peptides MART-1/Melan-A27–35 or tyrosinase1–9, as well as IFN-γ–releasing KLH-specific T cells, in two of six vaccinated melanoma patients, but do not support an association between the induction of these T cells and clinical responses.
30
Immunotherapy of melanoma
TL;DR: Tumour immunology is now on solid technical and conceptual footing, however, the challenge remains to apply to patients the results obtained in the laboratories, and to greatly accelerate the development of new anticancer vaccines.
30
T cell-mediated immune responses in melanoma: Implications for immunotherapy
TL;DR: This work has attempted to identify MHC class II-restricted tumor antigens recognized by tumor-specific CD4+ T cells, which play a central role in orchestrating the host immune response against cancer.
30
Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination
Julia Karbach,Sacha Gnjatic,Claudia Pauligk,Armin Bender,Markus Maeurer,Joachim L. Schultze,Kerstin Nadler,Claudia Wahle,Alexander Knuth,Lloyd J. Old,Elke Jäger +10 more
TL;DR: The results show that immunization with NY‐ESO‐1 peptides leads to strong tumor‐reactive CD8+ T‐cell responses, and suggest that approaches to peptide vaccination may be improved to induce higher numbers of antigen‐specific T‐cells and to selectively increase the proportion of CD8-T‐cells that have the capacity to recognize and eliminate tumor cells.
30
Therapeutic vaccines: realities of today and hopes for the future.
TL;DR: Vaccines are by definition prophylactic, but in recent years an interest has developed in therapeutic vaccines for infectious diseases such as AIDS and tuberculosis, as well as gastric ulcers, cancer, and autoimmune diseases and there are potential vaccines in development for myasthenia gravis, lupus and diabetes.
29
References
Tolerance, danger, and the extended family.
TL;DR: The possibility that the immune system does not care about self and non-self, that its primary driving force is the need to detect and protect against danger, and that it does not do the job alone, but receives positive and negative communications from an extended network of other bodily tissues is discussed.
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P. van der Bruggen,Catia Traversari,Patrick Chomez,Christophe Lurquin,E De Plaen,B Van den Eynde,Alexander Knuth,Thierry Boon +7 more
TL;DR: In this paper, a gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, which belongs to a family of at least three genes.
3.7K
Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity
Glenn Dranoff,Elizabeth M. Jaffee,Audrey J. Lazenby,Paul Golumbek,Hyam I. Levitsky,Katja Brose,Valerie Jackson,Hirofumi Hamada,Drew M. Pardoll,Richard C. Mulligan +9 more
TL;DR: The results have important implications for the clinical use of genetically modified tumor cells as therapeutic cancer vaccines and the levels of anti-tumor immunity reported previously in cytokine gene transfer studies involving live, transduced cells could be achieved through the use of irradiated cells alone.
3K
GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
TL;DR: It is demonstrated that cooperation between GM-CSF and tumour necrosis factor-α (TNF-α) is crucial for the generation of human dendritic/Langerhans cells from CD34+ haematopoietic progenitors.
1.6K
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
Thomas Wölfel,M. Hauer,Jörg Schneider,Manuel Serrano,Catherine Wölfel,E Klehmann-Hieb,E De Plaen,Thomas Hankeln,K H Meyer zum Büschenfelde,D Beach +9 more
TL;DR: Results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a.
1.2K